SCHEMBL6790341

SCHEMBL6790341

CC(=O)N1CC(CCN2CCC(c3ccc(C)cc3)CC2)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.55
HTR1A P08908 1/20 0.55
HTR2A P28223 1/20 0.55
NOTUM Q6P988 1/20 0.44
SLC18A3 Q16572 2/20 0.44
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
SIGMAR1 Q99720 2/20 0.42
MCHR1 Q99705 1/20 0.42
DRD4 P21917 3/20 0.42
DRD3 P35462 2/20 0.42
KCNH2 Q12809 2/20 0.41
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
OPRM1 P35372 2/20 0.39
OPRL1 P41146 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11839176 0.92 DRD2 (0.57) DRD2HTR1AHTR2ANOTUMSLC18A3
SCHEMBL28752384 0.89 DRD2 (0.55) DRD2HTR1AHTR2ANOTUMSLC18A3
SCHEMBL11823970 0.88 DRD2 (0.52) DRD2HTR1AHTR2ANOTUMSLC18A3
SCHEMBL6792592 0.86 DRD2 (0.52) DRD2HTR1AHTR2ANOTUMSLC18A3
SCHEMBL6796674 0.84 DRD2 (0.63) DRD2HTR1AHTR2ANOTUMDRD4
SCHEMBL3958993 0.82 DRD2 (0.51) DRD2HTR1AHTR2ANOTUMSLC18A3
SCHEMBL9014839 0.81 DRD2 (0.54) DRD2HTR1AHTR2ASLC18A3SIGMAR1
SCHEMBL7216011 0.78 DRD2 (0.50) DRD2HTR1AHTR2ANOTUMADRA1B
SCHEMBL11833053 0.77 SLC18A3 (0.45) DRD2HTR1AHTR2ASLC18A3SIGMAR1
SCHEMBL9014725 0.77 KCNH2 (0.63) DRD2HTR1AHTR2ASLC18A3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040044007-A1 Indoline derivatives H. LUNDBECK A/S (DK) 2004-03-04 US claimed
US-20040044007-A1 Indoline derivatives H. LUNDBECK A/S (DK) 2004-03-04 US disclosed
EP-1345921-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. Lundbeck A/S (DK) 2003-09-24 EP disclosed
WO-2002051833-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. LUNDBECK A/S (DK) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044007-A1 Indoline derivatives CNR1, GRIN2C, HTR3C DRD2 43/4885HTR1A 7/4885HTR2A 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.